Last $15.64 USD
Change Today +1.92 / 13.99%
Volume 459.3K
GALT On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
NASDAQ CM
As of 10:55 AM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

galectin therapeutics inc (GALT) Snapshot

Open
$14.03
Previous Close
$13.72
Day High
$15.95
Day Low
$13.95
52 Week High
02/26/14 - $19.11
52 Week Low
07/25/13 - $4.55
Market Cap
342.6M
Average Volume 10 Days
174.9K
EPS TTM
$-0.84
Shares Outstanding
21.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GALECTIN THERAPEUTICS INC (GALT)

Related News

No related news articles were found.

galectin therapeutics inc (GALT) Related Businessweek News

No Related Businessweek News Found

galectin therapeutics inc (GALT) Details

Galectin Therapeutics Inc., a development stage company, is engaged in the research and development of therapies for fibrotic disease and cancer. The company’s lead product candidates include GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis and fatty liver disease for which the company intends to initiate a Phase I clinical trial in patients with non-alcoholic steatohepatitis; and GM-CT-01, a linear polysaccharide polymer comprising mannose and galactose that is in a Phase I/II clinical trials in Europe as a combination with a tumor vaccine in patients with advanced melanoma, a skin cancer. Galectin Therapeutics Inc., through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

6 Employees
Last Reported Date: 03/21/14
Founded in 2000

galectin therapeutics inc (GALT) Top Compensated Officers

Chief Executive Officer, President, Chief Med...
Total Annual Compensation: $569.7K
Executive Chairman
Total Annual Compensation: $360.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $127.3K
Chief Operating Officer and Corporate Secreta...
Total Annual Compensation: $260.0K
Compensation as of Fiscal Year 2013.

galectin therapeutics inc (GALT) Key Developments

Galectin Therapeutics Announces First Patient Dosed in Cohort 1 of Phase 1B Clinical Trial of GR-MD-02 in Combination with Ipilimumab in Metastatic Melanoma

Galectin Therapeutics Inc. announced that the first patient has been dosed in cohort 1 of the Company's Phase 1B clinical trial evaluating GR-MD-02 in combination with ipilimumab (Yervoy(R)) in patients with metastatic melanoma. Providence Portland Medical Center's Earle A. Chiles Research Institute (EACRI), a leader in immunotherapy research and translational clinical trials in melanoma and other cancers, is conducting the study under principal investigator Brendan D. Curti, M.D. The study employs a 3+3 Phase 1 design with dose escalation of GR-MD-02, a galectin inhibitor, in conjunction with the standard therapeutic dose of ipilimumab in patients with advanced melanoma for whom ipilimumab would be considered standard of care. Cohort 1, which seeks to enroll at least 3 patients (and up to 6 should there be drug associated adverse events), will utilize 1 mg/kg of GR-MD-02 administered one hour before 3 mg/kg of ipilimumab on days 1, 22, 43 and 65. Researchers will assess the effects of GR-MD-02 with ipilimumab on melanoma response by inducing proliferation, activation and memory function of CD8+ T cells. In addition to monitoring for toxicity and clinical response, blood samples will be obtained to assess immunologic measures relevant to galectin biology and ipilimumab T-cell check-point inhibition.

Galectin Therapeutics, Inc.(NasdaqCM:GALT) added to Russell 2000 Index

Galectin Therapeutics, Inc. will be added to the Russell 2000 Index.

Galectin Therapeutics, Inc.(NasdaqCM:GALT) added to Russell 3000 Index

Galectin Therapeutics, Inc. will be added to the Russell 3000 Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GALT:US $15.94 USD +2.22

GALT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GALT.
View Industry Companies
 

Industry Analysis

GALT

Industry Average

Valuation GALT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 10.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALECTIN THERAPEUTICS INC, please visit www.galectintherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.